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Purpose The aim of this study is to assess autonomic function by analyzing heart rate 
variability (HRV) at rest and during submaximal exercise in OSA patients and a non-
OSA control group. 
Methods Subjects were classified as OSA (n=10) or non-OSA (n=16) based on results 
from an at-home sleep assessment.  Height, weight, waist and neck circumferences, and 
body composition were collected during the first visit for each subject.  Physical activity 
during the day and nocturnal movement were assessed over a period of 4 days, including 
3 weekdays and 1 weekend day, using accelerometers.  HRV and blood pressure were 
recorded at rest (visit 2) and during a submaximal graded exercise test (visit 3).  HRV 
variables that were not normally distributed were log transformed before statistical 
analysis.  Independent samples t-tests were used to establish differences between groups.  
Pearson correlations were calculated to determine relationships between OSA and HRV 
in terms of age and BMI.  If there was a significant correlation between variables and age 
and/or BMI, then a repeated measures ANCOVA was used with age or BMI as the 
covariate.  If there was not a significant correlation, a repeated measures ANOVA was 
utilized. 
Results At rest, the OSA group had lower SDNN, RMSSD, and Total Power (p<0.05).  A 
higher LF-HF ratio was found in the control group than the OSA group during exercise 
(p<0.05).  LFnu and HFnu were trending towards significance, both higher in the OSA 
group (p=0.066 and p=0.075, respectively) during exercise indicating that the OSA group 
did not experience parasympathetic withdrawal.  All subjects participate in about 30 




Discussion Results suggest that the OSA population may have increased autonomic 
dysfunction during exercise due to sympathetic dominance and a blunted parasympathetic 
response during steady-state exercise.  Potential mechanisms for autonomic imbalances 
include decreased chemoreceptor and baroreceptor sensitivity.  Further research with a 










































Obstructive sleep apnea (OSA) is a sleep disordered breathing syndrome caused 
by the complete collapse of the pharyngeal airway.
1,2
 Apneas are pauses in respiration 
“associated with ongoing ventilatory effect” lasting at least ten seconds.
1,3
 Hypopneas are 
decreases in airflow combined with at least a 4 percent decrease in oxygen saturation due 
to a partial collapse of the pharyngeal airway.
1
 OSA affects about 3 to 7 percent of adult 
males and 2 to 5 percent of adult females, totaling 15 million adult Americans.
1,4
 In older 
adults over the age of 65, the prevalence of OSA increases 2-3 fold compared to middle-
aged adults between the ages of 30-64 years old.
5
 Even though 15 million adult 
Americans have OSA, at least 85% of cases are undiagnosed.
6
 With the rise of obesity in 
America, the number of people with OSA is increasing.
7
 Roughly 1 in 5 adults has at 
least mild OSA and 1 in 15 adults have moderate or severe OSA.
6
 
The severity of OSA is determined by the apnea-hypopnea index (AHI) which is 
measured by the number of apneas or hypopneas (also known as an “event”) per hour of 
sleep.
2
 According to the AHI scale: mild OSA is 5 to 15 events per hour, moderate OSA 
is 15 to 30 events per hour, and severe OSA is greater than 30 events per hour.
2
 One is 
diagnosed with OSA when he/she has at least five events per hour combined with 
excessive daytime sleepiness.
1
 The most absolute way to diagnose OSA is the 
polysomnography method. This method requires the patient to participate in an overnight 
sleep study.
6,8
 The variables monitored and measured include the electroencephalogram, 
electromyogram, electrocardiogram, snoring, and respiration—flow, effort, and oxygen 
saturation.
6






 Since polysomnography is an expensive method to detect OSA, 
heart rate variability has been used to assesses autonomic function.
6
 
Numerous studies have established known risk factors for developing OSA. The 
most important and controllable risk factor is obesity.
2,3,7,10
 In the four-year follow-up 
Wisconsin Sleep Cohort Study, it was found that a 10 percent increase in weight yielded 
a six-fold increase in risk of developing OSA.
5
 Approximately 70 percent of people with 
sleep apnea are also obese.
3
 Other risk factors include male gender, large neck 
circumference, increased waist circumference and central body fat, and habitual 
snoring.
1,5,11
 However, it should be noted that not everyone with OSA is male, obese, 
tired, middle-aged, and snores.
5
 Anatomical risk factors include hypertrophic tonsils, high 
modified Mallampati grade, narrowing of palate or oropharyngeal walls, mandibular 
retrognathia (“overbite”), and small crico-mental space.
11
  Mallampati grade is a test that 
examines what is visible when a subject opens their mouth.  For example, whether or not 
the tonsils, soft palate, and uvula are visible; if a subject receives a higher score, they are 
more likely to experience airway obstruction.
12
  Crico-mental space is determined “using 
a thin ruler to connect the cricoid cartilage to inner mentum.  This line is then bisected 
and the perpendicular distance to the skin of neck is measured.”
13
  There is also 
inconclusive evidence that genetics, smoking, menopause, alcohol use before sleep, and 
nighttime nasal congestion increase the risk of developing OSA.
5
 
Common symptoms of people who develop OSA include loud and habitual 
disruptive snoring, breathing pauses during sleep, unwarranted daytime sleepiness, sexual 
dysfunction, and nocturnal choking and gasping.
1,5
  These symptoms have been related to 




decrease in quality of life.
5
  Sleep apnea has also been linked to various cardiovascular 
diseases including but not limited to hypertension, coronary artery disease, myocardial 
infarction, congestive heart failure, and stroke.
5
 In addition, there have been associations 
between OSA and diabetes and metabolic syndrome.
2,5
 
The pathophysiology of OSA is complex and varies among patients. The most 
common causes are deficient pharyngeal anatomy and unsteady upper airway dilator 
muscle control while awake and asleep.
1,3,14
 When a person is awake, the upper airway 
dilator muscles are activated and used for speech, breathing, and swallowing. During 
sleep, the dilator muscles relax and are more likely to collapse.
15
 The collapsing of the 
airway can be attributed to negative pressure in the airway and positive pressure outside 
the airway.
3
 A study by Isono et al. found that patients with sleep apnea had smaller 
pharyngeal airways and increased collapsibility compared to the control group.
16
 
Increased negative intraluminal pressure and narrowing of the pharyngeal airway has also 
been found to contribute to this pathophysiology.
11
 Another mechanism of OSA is the 
nocturnal loss of lung volume that decreases the traction on the upper airway increasing 
the collapsibility.
1,17
 This is caused by the excess fat around on the neck. Localized fat 
around the neck may also contribute to increased metabolic demand and amplified 
breathing effort.
17
 The lack of stability of the ventilatory control system may also cause 
OSA by the partial or complete collapse of the pharyngeal airway.
1
 OSA 
pathophysiology could derive from changing surface tension in the airway, arousal 
threshold, and asynchronous timing of activation of upper airway compared to pump 
muscles.
1






 The decrease in autonomic function can be measured by 
heart rate variability. 
Obstructive sleep apnea is related to cardiovascular diseases. More specifically, in 
patients with hypertension OSA is 30 to 83 percent higher, 12 to 53 percent higher in 
those with heart failure, 30 to 58 percent higher in those with ischemic heart diseases, and 
43 to 91 percent higher in patients who have had a stroke.
19
 OSA and cardiovascular 
disease (CVD) do not necessarily have a causal relationship. However, OSA may hasten 
the rate of progression of any CVD including hypertension. In a four-year follow up 
study of the Wisconsin Sleep Cohort Study, researchers found a dose-response 
relationship between sleep apnea and the occurrence of hypertension four years later.
20,21
 
The vasoconstriction in the periphery is a result of an apnea. When the person is able to 
breathe again, there is increased venous return and cardiac output against the 
vasoconstricted periphery which causes a rise in blood pressure. It has been documented 
that person without hypertension can reach up to 250/110 mmHg after an apnea.
18
 There 
are numerous potential mechanisms that attribute OSA affecting CVD: vascular injury, 
acceleration of atherosclerosis due to hypoxemia, chronic sympathetic hyperactivity, 
hypertension, heart failure.
14
 The American Heart Association (AHA) proposes the 
following potential mechanisms: sympathetic activation, cardiovascular variability, 
vasoactive substances, inflammation, oxidative stress, endothelial dysfunction, insulin 
resistance, thrombosis, and intrathoracic pressure.
1
 
OSA causes a lack of oxygen in the body when one has an event which causes 
autonomic dysfunction.  Two primary mechanisms that cause this imbalance in the 




chemoreceptor sensitivity.  Baroreceptors detect changes in blood pressure and aim to 
keep it within a normal range.  When people with OSA experience hypoxia throughout 
the night, blood pressure rises.  This reoccurring cycle desensitizes the baroreceptors 
which results in raising the detection level in which they perceive high blood pressure.
22
  
As this level increases, the baroreceptors are more tolerant of higher blood pressures that 
they once detected increasing the likelihood of hypertension in this population.
22
  Higher 
blood pressure increases sympathetic activity causing an imbalance in the autonomic 
nervous system.  During hypoxia, chemoreceptors detect lack of oxygen and increased 
carbon dioxide.  This heightens the sympathetic nervous system resulting in increased 
heart rate and breathing and vasoconstriction thereby increasing blood pressure.
23
  
Reoccurring hypoxias increase the sensitivity of the chemoreceptors ultimately increasing 
the initiation of sympathetic nervous system when oxygen desaturation is detected.
23
 
Patients with OSA have decreased heart rate variability (HRV) and increased blood 
pressure variability. The decreased heart rate variability is potentially the connecting 
factor between OSA and CVD.
1
 
HRV is the physiologic changing of the heart rate over time based on the 
interaction between the sympathetic and parasympathetic nervous systems which 
measures autonomic function.
4,24
 It is measured by the changes in variation from R-R 
intervals and is caused by heart rate, blood pressure, and respiration rate.
18,24-26
 HRV is 
influenced by the changes in the autonomic nervous system, caused by both internal and 
external stimuli, on the sinoatrial node. Measuring autonomic nerve function within the 
cardiovascular system can be done by monitoring HRV.
4
 In persons with OSA a decrease 
in HRV is believed to represent a decrease in autonomic control.
27




in autonomic nerve function is detected by decreased HRV and may be associated with 
diseases such as renal failure, liver insufficiency, diabetes, congestive heart failure, and 
myocardial infarction.
4
 Narkiewicz et al evaluated cardiovascular variability in OSA 
patients without CVD. The patients were divided into 3 groups: mild OSA, moderate to 
severe OSA, and a control group. It was found that patients with moderate to severe OSA 
had significantly shorter RR intervals, faster heart rate, increased sympathetic burst 
frequency, and changing blood pressure.
18
 They concluded that “cardiovascular 
variability is altered in patients with OSA, even in the absence of hypertension, heart 
failure, or other disease states; and the degree of derangement in cardiovascular 
variability may be linked to the severity of OSA.”
18
  
HRV can be analyzed using time-domain and frequency-domain measures.
28
 
Time-domain measures include the standard deviation of all NN or RR intervals (SDNN), 
the square root of the mean of the sum of squares of differences between adjacent NN or 
RR intervals (RMSSD), and the division of the number of interval differences of 
successive NN intervals greater than 50ms by the total number of NN intervals 
(pNN50).
29-31
 SDNN represents all cyclic components of variability. 
29-31
 RMSSD is the 
estimate of all short term components of HRV.
29-31
 Frequency-domain measures include 
total power, low frequency (LF), high frequency (HF), and the LF-HF ratio. The total 
power is the variance of NN intervals over the time period analyzed.
31
 The HRV 
spectrum is comprised of two parts: a LF band and a HF band. The HF band (0.15-0.4 
Hz) represents the parasympathetic system; the LF band (0.04-0.15 Hz) is related to both 
the parasympathetic and sympathetic systems.
32
 In a recent study, researchers compared 




electrocardiogram. The researchers found a higher LF power, a lower HF power, and a 
higher LF-HF ratio in OSA patients compared to the control subjects.
28
 This supports the 
evidence increased sympathetic activity and/or decreased parasympathetic activity in 
people with OSA.
28
 In patients with OSA, a decrease in HRV has been found but there is 
variance in the HRV among patients suffering from OSA.  The HRV pattern may be 




Many studies have evaluated the relationship between OSA and HRV. A study of 
78 patients with suspected OSA participated in an overnight polysomnography in which 
HRV was also measured. Those with severe OSA had an increased number of longer 
accelerated beats and a decreased number of deceleration beats indicating the lack of 
balance between accelerations and decelerations in heart rate.
33
  An increase in cardiac 
sympathetic drive is seen in patients with OSA during resting wakefulness depicted by 
faster heart rates.
1
  There is also an increase in the activity of the parasympathetic 
nervous system in OSA patients during sleep which suggests that it is related to 
mechanisms compensating oxygen saturation changes.
25
  In another study, it was found 
that patients with severe OSA had a shorter R-R interval during the night.
24
 OSA and 
blunted HRV are both risk factors for cardiovascular disease which may cause 
mortality.
27
 In comparison to similar obese control subjects, awake OSA patients at rest 
have decreased HRV and increased blood pressure variability.
1
  Unfavorable outcomes 
are expected in those with cardiovascular disease and diminished HRV.
1
  According to 
the Framingham Heart Study, lower HRV is a risk factor to the development of 




risk of organ damage in those with cardiovascular disease.
1
  In the Wisconsin Sleep 
Study, a relationship between OSA and hypertension was confirmed.
2
  OSA patients are 
more likely to develop coronary artery disease, cerebrovascular disease, atherosclerosis, 
arterial stiffness, cardiac arrhythmias, and heart failure.
2
 
It is still unknown as to whether or not OSA limits exercise capacity.  It can be 
assumed that because people with OSA have increased daytime sleepiness, there would 
be a decreased desire to engage in physical activity and are more exhausted at a given 
workload.
34
  The combination of unwarranted daytime sleepiness and fatigue could 
potentially impact the difficulty of exercise for people with OSA.  Levels of fatigue may 
be increased at lower intensity exercise due to the overloading of dilator muscles after an 
apnea occurs.
35
  Studies have observed the impact that exercise training has on the 
severity of OSA.  A meta-analysis by Iftikhar et al. examined the effectiveness of 
exercise training in OSA patients in terms of severity, BMI, sleep efficiency, daytime 
sleepiness, and cardiovascular fitness.
36
  Interestingly, the researchers found that despite 
changes in BMI and body weight, exercise does have a significant effect on AHI.
36
  
Exercise training was able to decrease the severity of the patients’ OSA. 
As previously mentioned, OSA increases the risk for developing CVD including 
faster heart rate, longer heart rate recovery period, longer QT-interval, and longer P-wave 
duration.
37
  Longer P-wave and QT-interval durations increase the likelihood of an 
abnormal heart rhythm.  There is a four-fold increase for atrial fibrillation if a patient has 
severe OSA at rest.
37
  The question then arises whether or not exercise is safe for people 
with OSA.  During exercise there is a higher risk for experiencing an abnormal heart rate 




catecholamines potentially causing increased abnormal automaticities and related 
premature beats.
38
  Arrhythmias are also common in people with OSA.  For example, the 
risk for ventricular tachycardia, second degree atrioventricular block, and premature 
ventricular contractions is higher in the OSA population.
39,40
  An increased resting heart 
rate and cardiovascular events have shown to be associated in many studies although 
“few studies have looked at the impact of OSA on HR.”
37
  Investigating this impact will 
give greater insight into how the autonomic nervous system responds to exercise when it 
is altered because of OSA.  It is unknown whether acute exercise would increase the 
likelihood of a patient with untreated OSA to have abnormal heart rhythms and if 
exercise would be safe for this population. 
Purpose: 
This study analyzed HRV at rest and during submaximal exercise in OSA patients and a 
control group. 
Hypothesis: 
We hypothesized that during exercise, autonomic function measured via HRV would be 
blunted in OSA patients as compared to a control group. 
Limitations: 
Subjects often overestimated or underestimated their physical activity levels. 
Delimitations: 






Subjects who were using medications that may influence heart rate were excluded from 
this study. 







The researchers recruited twenty persons with obstructive sleep apnea (OSA) 
from James Madison University and the Rockingham Memorial Hospital Center for 
Sleep Medicine in Harrisonburg, Virginia. In addition, a non-OSA control group was 
recruited. Inclusion criteria for subjects included males and females at least eighteen 
years old with a minimum BMI of 25 kg/m
2
.  Exclusion criteria for subjects included 
known cardiovascular disease, congestive heart failure, or pulmonary disease, and being 
in the “high risk for atherosclerotic cardiovascular disease” category as defined by the 
American College of Sports Medicine.
41
  The International Physical Activity 
Questionnaire Short Form (IPAQ) was used to exclude those who were highly physically 
active in order to eliminate the potential influence of regular physical activity on the 
study’s outcomes.  Any persons taking medications that could potentially influence heart 
rate and HRV were also excluded.  Participants were asked to report to the Human 
Performance Laboratory (HPL) in Godwin Hall at James Madison University on three 
separate occasions for a total of two and a half hours.  All procedures were approved by 
the JMU Institutional Review Board (IRB). 
Visit 1 
Before the testing began, all subjects completed a health history questionnaire 
(HHQ) in order to provide basic health information and to identify any potential 
exclusion criteria as well as three additional questionnaires.  The Berlin Questionnaire 




factors for OSA and their level of snoring, and the Epworth Sleepiness Scale (ESS) was 
used to establish daytime sleepiness levels. 
Body Mass and Height 
Subjects had their body weight and height measured using a physician’s scale and 
stadiometer, respectively.  The subjects removed their shoes, excess/layered clothing, and 
any items in their pockets before stepping on to the scale.  Body weight was measured to 
the nearest 0.5 lbs and converted to kilograms.  Height was measured with a stadiometer 
to the nearest 0.5 cm.  Waist and neck circumferences measurements were taken using a 
cloth tape measure with a spring-loaded handle to reduce the compression of the skin.  
The waist circumference was measured directly above the subject’s iliac crest.  The neck 
circumference was measured around the widest part of the subject’s neck. 
Anthropometry  and Body Composition 
Body composition was analyzed using a Dual-Energy X-Ray Absorptiometer 
(Lunar iDXA 1RME+200072 (14.10), Madison, Wisconsin).  The scan consists of total 
body/visceral fat and bone mineral density.  The subject was symmetrically centered 
within the white outer lines on the bed with their spine and head along the center line.  If 
the subject could not fit within the white box, he or she was adjusted so that their entire 
right side fit within the box.  The DEXA is capable of estimating total body fat based on 











 Plus, San Diego, California) was used to screen 
for the presence of OSA.  The research staff thoroughly explaind to the participants how 
to setup and use the ApneaLink
TM
 at-home screening device.  When subjects returned the 
ApneaLink
TM
 the following day, the data collected by the device was downloaded using 
the ApneaLink
TM 
software.  The software analyzed the number of events per hour the 
subject had as well as the amount of snoring, oxygen saturation levels, and sleep latency.  
A certified sleep technician and sleep physician reviewed the sleep data collected by the 
ApneaLink
TM
.  In addition, subjects were given an accelerometer (ActiGraph, GT3X-
Plus, Pensacola, Florida) to assess nocturnal movement.  The ActiGraph is a small device 
worn on their non-dominant wrist during sleep and was attached to a watch in order to 
prevent insignificant movement of the accelerometer.  Participants were instructed to 
record the times that they went to bed and the time they got out of bed on a log sheet and 
to note any abnormalities that may have occurred during sleep.  The ActiGraph was worn 
for 4 days including 3 weekdays and 1 weekend day. 
Physical Activity Assessment 
The ActiGraph accelerometer was also utilized to assess the subjects’ daily 
physical activity levels.  Subjects wore the accelerometer on the waistband of their right 
waist line mid-thigh.  Subjects were asked to continue their normal daily activities and to 
document any abnormal physical activities.  After the four days of physical activity 
assessment, subjects returned the accelerometer device to the HPL, and continued with 





Heart Rate Variability Assessment 
Each subject completed HRV measurements, heart rate, and blood pressure 
measurements at rest.  Heart rate and HRV were measured using a Polar RS800CX 
monitor (Kempele, Finland).  The monitor’s data was saved to the Polar watch which was 
downloaded using the Polar Pro Training 5 software.  Subjects laid supine in a darkened 
room while the heart rate and HRV were monitored over a 15 minute time period.  In 
addition, resting hemodynamic values was assessed using a non-invasive bioimpedance 
device (PhysioFlow FP-05 Lab 1, NeuMeDx, Bristol, Pennsylvania). Subjects were asked 
to breathe in synchronization with a metronome at 12 beats per minute to control for the 
effect of respiration on the HRV variables. 
The HRV variables are based on frequency or time-domain.  Frequency based 
variables include total power (TP), LF, HF, and LF-HF ratio.  TP (msec
2
) measures the 
energy in the heart from 0 to .40 Hz.
42
  LF (msec
2
) is the energy in the heart from 0.04 to 
0.15 Hz.  There is numerous controversial research stating that LF does not solely 
represent sympathetic activity but also represents parasympathetic drive.
29,30
  According 
to Massimo Pagani’s research group, the LF component shows cardiac sympathetic 
flow.
30
  HF (msec
2
) is the energy in the heart from 0.15 to 0.40 Hz and represents 
parasympathetic activity.  Malliani, Lombardi, and Pagani found in healthy human 
subjects and animal experiments, the LF factor of heart rate and arterial pressure 
variability was increased by moderate hypotension, physical activity, and the occlusion of 
the coronary or carotid arteries.
43




decrease in the HF factor.  The HF factor of HRV was increased in humans by controlled 
respiration, cold stimulation of the face, and rotational stimuli.
43
  The LF-HF ratio is 
simply the ratio between the LF and the HF power and reflects sympathovagal balance.
42
  
The ratio also shows the relative sympathetic input of the control of one’s heart rate.
30
  
The time domain variables include pNN50, SDNN, and rMSSD.  pNN50 is a percentage 
of differences between consecutive R-R intervals greater than 50 msec.  SDNN (msec) is 
the standard deviation of all normal R-R intervals during the recording and is related to 
total power.  rMSSD (msec) is the square root of the mean of the squares of differences 
between consecutive R-R intervals and reveals parasympathetic activity.
42
 
Resting Blood Pressure 
Seated blood pressure was measured after the resting HRV assessment via 
auscultation. 
Visit 3 
Submaximal Exercise Test 
Subjects completed a two-stage, sub-maximal graded exercise test on the 
treadmill.  Before the exercise test, maximal fitness level (VO2max) was predicted using a 
validated regression equation based on age, gender, physical activity status, and BMI.
42
 
The treadmill speed was set to 3.5 miles per hour; the incline was individually adjusted 
based on predicted VO2max corresponding to a light intensity (35% VO2 reserve
41
) and a 
vigorous intensity (70% VO2 reserve
41
).  Subjects walked for a period of five minutes at 
each intensity level.  Heart rate and HRV were continuously monitored throughout the 




monitored at each stage and during exercise recovery.  Similar to resting hemodynamic 
values obtained during visit 2, cardiovascular hemodynamic variables were obtained 
throughout exercise and recovery using the PhysioFlow and a Metabolic Cart (Parvo 
Medics True One 2400 Metabolic Measurement System, Sandy, Utah).  Exercise tests 
were terminated if subjects reach 85% of their predicted maximal heart rate reserve in 
accordance with the published ACSM guidelines for sub-maximal exercise tests.
41
  The 
test was also terminated if any subjects had contraindications during the exercise test 




Statistical analysis was performed using SPSS.  Subject characteristics were 
reported as means ± standard deviation.  Statistical significance was set at p < 0.05.  HRV 
variables that were not normally distributed were log transformed before statistical 
analysis.  Normalized LF (LFnu) was calculated as LFnu = LF/(TP-VLF)*100 and 
normalized HF (HFnu) was calculated as HFnu = HF/(TP-VLF)*100.  Independent 
samples t-tests were utilized to identify baseline differences between the OSA group and 
control group.  Pearson correlations were calculated to determine relationships between 
age and BMI.  If a significant effect of age or BMI was observed, then an analysis of 
covariance (ANCOVA) was used with an adjustment.  If the effect of age or BMI was not 











The Effects of Obstructive Sleep Apnea (OSA) on Autonomic Function 




Purpose The aim of this study is to assess autonomic function by analyzing heart rate 
variability (HRV) at rest and during submaximal exercise in OSA patients and a non-
OSA control group. 
Methods Subjects were classified as OSA (n=10) or non-OSA (n=16) based on results 
from an at-home sleep assessment.  Height, weight, waist and neck circumferences, and 
body composition were collected during the first visit for each subject.  Physical activity 
during the day and nocturnal movement were assessed over a period of 4 days, including 
3 weekdays and 1 weekend day, using accelerometers.  HRV and blood pressure were 
recorded at rest (visit 2) and during a submaximal graded exercise test (visit 3).  HRV 
variables that were not normally distributed were log transformed before statistical 
analysis.  Independent samples t-tests were used to establish differences between groups.  
Pearson correlations were calculated to determine relationships between OSA and HRV 
in terms of age and BMI.  If there was a significant correlation between variables and age 
and/or BMI, then a repeated measures ANCOVA was used with age or BMI as the 
covariate.  If there was not a significant correlation, a repeated measures ANOVA was 
utilized. 
Results At rest, the OSA group had lower SDNN, RMSSD, and Total Power (p<0.05).  A 
higher LF-HF ratio was found in the control group than the OSA group during exercise 




group (p=0.066 and p=0.075, respectively) during exercise indicating that the OSA group 
did not experience parasympathetic withdrawal.  All subjects participate in about 30 
minutes of moderate physical activity daily. 
Discussion Results suggest that the OSA population may have increased autonomic 
dysfunction during exercise due to sympathetic dominance and a blunted parasympathetic 
response during steady-state exercise.  Potential mechanisms for autonomic imbalances 
include decreased chemoreceptor and baroreceptor sensitivity.  Further research with a 








 Obstructive sleep apnea (OSA) is a sleep disorder characterized by the partial 
and/or complete collapse of the pharyngeal airway in addition to excessive daytime 
sleepiness.
1,2
  An apnea occurs when there is a total collapse of the pharyngeal airway 
lasting at least ten seconds.
1,3
  A partial collapse airway combined with at least a 4 
percent decrease in oxygen saturation is referred to as a hypopnea.
1
  OSA affects 
approximately 15 million adult Americans
1,4
; however, it is estimated that at least 85% of 
cases are undiagnosed.
5
  In adults over the age of 65, the prevalence increases two-to-
three fold compared to adults between the ages of 30-64 years old.
6
  With the rise of 
obesity in America, the number of people with OSA is likely increasing.
7
 This disorder 
has been found to be related to a rise in vehicular crashes, psychosocial problems, 
decreases in cognitive function, and a decrease in quality of life.
6
  This syndrome has also 
been linked to various cardiovascular diseases such as hypertension, coronary artery 
disease, myocardial infarction, congestive heart failure, and stroke.
6
 
The most common and controllable risk factor for OSA is obesity.
2,3,7,8
  Roughly 
70% of people with sleep apnea are also obese.
3
  Other risk factors include male gender, 
large neck circumference, increased waist circumference, habitual snoring, and upper 
airway structural abnormalities.
1,6,9
  Structural abnormalities include enlarged tonsils, 
narrowing of palate or oropharyngeal walls, and mandibular retrognathia.
9
  There is 
inconclusive evidence that genetics, smoking, menopause, alcohol use before sleep, and 
nighttime nasal congestion increase the risk for developing OSA.
6
   
 The pathophysiology of OSA is complex and varies among patients.  The most 




muscle control while awake and asleep.
1,3,10
  During wakefulness, a person is in control 
of their dilator muscles as they are used for speech, breathing, and swallowing.  During 
sleep, the dilator muscles relax and are more likely to collapse.
11
  
The pathophysiology mechanisms of OSA result in sympathetic overdrive 
impacting the autonomic nervous system.
12
  Two potential mechanisms that cause this 
imbalance in the autonomic nervous system include decreased baroreceptor sensitivity 
and increased chemoreceptor sensitivity.  Baroreceptors detect changes in blood pressure 
and aim to keep it within a normal range.  When people with OSA experience hypoxia 
throughout the night, blood pressure rises.  This reoccurring cycle desensitizes the 
baroreceptors which results in raising the “set point” or level in which they detect the 
high blood pressure.
13
  As this level increases, the baroreceptors are less sensitive to the 
higher blood pressures.
13
  When the baroreceptors become desensitized, a rise in blood 
pressure is not countered by a reduction in sympathetic activity, thereby contributing to 
an autonomic imbalance.  During hypoxia, chemoreceptors detect lack of oxygen and 
increased carbon dioxide.  This heightens the sympathetic nervous system resulting in 
increased heart rate, breathing, and vasoconstriction thereby increasing blood pressure.
14
  
Reoccurring hypoxias increase the sensitivity of the chemoreceptors ultimately increasing 
the initiation of sympathetic nervous system when oxygen desaturation is detected.
14
  
Additionally, patients with OSA also have faster heart rates while awake, potentially 
signifying a heightened sympathetic nervous system.
1
  The aroused sympathetic nervous 
system in people with sleep apnea creates an imbalance in the autonomic nervous system, 
specifically between the sympathetic and parasympathetic nervous systems.  The 




 HRV is the physiologic changing of the heart rate over time based on the 
interaction between the sympathetic and parasympathetic nervous system.
4,15
  It is 
measured by the changes in variation from R-R (also known as N-N) intervals and is 
caused by heart rate, blood pressure, and respiration rate.
12,15-17
  A decrease in autonomic 
control may be associated with diseases such as renal failure, liver insufficiency, 
diabetes, congestive heart failure, and myocardial infarction.
4
  Patients with moderate to 
severe OSA have significantly shorter R-R intervals, faster heart rate, increased 
sympathetic burst frequency, and changing blood pressure.
1,12,15
 
Although the relationship between OSA and HRV has been studied in both awake 
and asleep patients at rest, the relationship has not been examined during a bout of acute 
exercise.  Previous research has investigated autonomic function during exercise in 
untreated OSA subjects measured by heart rate and blood pressure recovery.
18
  The study 
found a decreased heart rate response in the OSA group during the recovery period 
suggesting autonomic dysfunction.
18
  Other studies have similarly found a decreased or 
blunted response in heart rate recovery after a bout of exercise.
19-21
 
It is also known that during exercise there is a higher risk for experiencing an 
abnormal heart rate or rhythm.  Exercise increases sympathetic activity and number of 
circulating catecholamines potentially causing increased automaticities and related 
premature beats.
22
  Arrhythmias are also common in people with OSA.  For example, 
there is a four-fold increase for atrial fibrillation if a patient has severe OSA
23
 and the risk 
for ventricular tachycardia, second degree atrioventricular block, and premature 
ventricular contractions is higher in the OSA population.
24-26,27,28
  The question then 




rate and cardiovascular events have shown to be associated in many studies although 
“few studies have looked at the impact of OSA on HR.”
23
  Investigating this impact will 
give greater insight into how the autonomic nervous system, measured directly by HRV, 
responds during an exercise session when it is altered because of OSA.  To date, no one 
has utilized HRV variables during exercise to further consider the autonomic dysfunction 
in OSA patients.  It is unknown whether acute exercise would increase the likelihood of a 
patient with untreated OSA to have abnormal heart rhythms and if exercise would be safe 
for this population.  Therefore, the purpose of this study is to analyze HRV at rest and 




 Twenty-six (26) people from the Harrisonburg, Virginia community, including 
James Madison University (JMU) and the Sentara Rockingham Memorial Hospital 
(RMH) Center for Sleep Medicine, were recruited for this study.  Subjects were all at 
least 18 years old with at least a BMI of 25 kg/m
2
.  Exclusion criteria included known 
cardiovascular disease, congestive heart failure, or pulmonary disease, and being in the 
“high risk for atherosclerotic cardiovascular disease” category as defined by the 
American College of Sports Medicine (ACSM).
29
  Any persons taking medications that 
could potentially influence heart rate and HRV were also excluded.  Highly active 
individuals (≥3 days of endurance exercise) and people who have received treatment for 
OSA were excluded from the study.  Subjects were asked to report to the Human 




a one week time period.  All procedures have been approved by the JMU and Sentara 




Before testing began, all subjects completed the consent form and several 
questionnaires.  Subjects completed a health history questionnaire to establish risk factors 
described in the ACSM guidelines.
29
  The Berlin Questionnaire and the Screening Tool 
for OSA (STOP) Questionnaire were used to establish risk factors for OSA and their 
level of snoring.  The Epwoth Sleepiness Scale (ESS) determined their level of daytime 
sleepiness.  The International Physical Activity Questionnaire Short Form was used to 
establish a baseline for each subject’s physical activity level. 
Anthropometry and Body Composition 
All subjects had their body weight using a physician’s scale and height measured 
using a stadiometer.  Body weight was recorded to the nearest 0.1 lbs and converted to 
kilograms; height was recorded to the nearest 0.25 cm.  Waist, hip, and neck 
circumferences were measured and followed the procedures described in the ACSM 
guidelines.
29
  Measures of total and regional body composition were measured using a 
dual-energy a-ray absorptiometer (Lunar iDEXA 1 RME+200072 (14.10), Madison, 
Wisconsin). 
At-Home Sleep Assessment 




 Plus, San Diego, California) for 






 include the AHI, snoring patterns, oxygen saturation levels, sleep latency, 
apneas, and hypopneas.  The OSA group had an AHI ≥ 5; the control group had an AHI < 
5.  Subjects also wore a wrist accelerometer (ActiGraph, GT3X-Plus, Pensacola, Florida) 
for 4 nights (3 weeknights and 1 weekend night) on their non-dominant wrist to assess 
nocturnal movement.  Participants recorded the times that they went to bed and the time 
they got out of bed on a log sheet and to note any abnormalities that may have occurred 
during sleep. 
Physical Activity Assessment 
An accelerometer was worn on each subject’s waistband of their right waist line 
mid-thigh for 4 days (3 weekdays and 1 weekend day).  Subjects reported anytime they 
did not wear the device, planned bouts of exercise, and any abnormal physical activities.  
The accelerometer measures activity based on movement counts per minute.
30
  The 
number of movement counts per minute determines the subject’s intensity.  The amount 
of time spent at the various intensity levels is reported in table 2.  Variables measured 
from the accelerometer include the following: the number of sedentary bouts and the 
duration of each bout; the amount of time spent being sedentary, participating in light, 
lifestyle, moderate, vigorous, and very vigorous physical activity; and the number of 
steps per day. 
Visit 2 
 
Heart Rate Variability Assessment 
 
Heart rate and HRV were measured using a Polar RS800CX monitor (Kempele, 
Finland).  The monitor’s data was saved to the Polar watch which was downloaded using 




while the heart rate and HRV were monitored over a 15 minute time period.  In addition, 
each subject’s resting blood pressure was measured according to the ACSM procedures.
29
  
Subjects were asked breathe in synchronization with a metronome at 12 beats per minute 
to control for the effect of respiration on the HRV variables. 
The HRV variables are based on frequency or time-domain.  Frequency based 
variables include total power, low frequency (LF), high frequency (HF), and LF-HF 
ratio.
31
  Total power is the variance of NN intervals over the time period analyzed (2 
minutes for this study).
32
  The LF and HF bands form the HRV spectrum.  The HF band 
(0.15-0.4 Hz) represents the parasympathetic system; the LF frequency band (0.04-0.15 
Hz) is associated with both the parasympathetic and sympathetic systems.
33
  There are 
three time domain variables.  The first is the standard deviation of all the NN intervals 
(SDNN).
32,34,35
  rMSSD is the square root of the mean of the sum of the squares of 
differences between adjacent NN intervals—estimate of all short term components of 
HRV.
32,34,35
  pNN50 is the division of NN50 (the number of interval differences of 




Subjects completed a two-stage, submaximal graded exercise test on the treadmill.  
Before the exercise test, maximal fitness level (VO2max) was predicted using a validated 
regression equation based on age, gender, physical activity status, and BMI.
31
  The 
treadmill speed was set to 3.5 miles per hour unless the subject could not tolerate this 




on the predicted VO2max corresponding to a light intensity (35% VO2 reserve
29
) and a 
vigorous intensity (70% VO2 reserve
29
).   
Subjects walked for five minutes at each intensity while heart rate, HRV, blood 
pressure, and ratings of perceived exertion variables were obtained.  Tests were 
terminated if any subjects had any contraindications during the exercise test as published 





Statistical analysis was performed using SPSS.  Subject characteristics are 
reported as means ± standard deviation.  Statistical significance was set at p < 0.05.  HRV 
variables that were not normally distributed were log transformed before statistical 
analysis.  Normalized LF (LFnu) was calculated as LFnu = LF/(TP-VLF)*100 and 
normalized HF (HFnu) was calculated as HFnu = HF/(TP-VLF)*100.  Independent 
samples t-tests were utilized to identify baseline differences between the OSA group and 
control group.  Pearson correlations were calculated to determine relationships between 
age and BMI.  If a significant effect of age or BMI was observed, then an analysis of 
covariance (ANCOVA) was used with an adjustment.  If the effect of age or BMI was not 




Twenty-six subjects were divided into two groups based on their AHI value.  




than the control group.  In addition, the OSA group had a significantly larger BMI, neck 
circumference, and waist circumference.  Sleep efficiency was significantly reduced in 
the OSA group (p = 0.013); there were no differences in any other sleep quality variables 
(Table 3).  BMI significantly correlated with average length of awakening (r = 0.55, p = 
0.005).  This was the only variable that significantly correlated with BMI; therefore no 
other variables were adjusted.  There were no differences in physical activity between the 
OSA and control groups (Table 2).  The subjects averaged 30 minutes of moderate 
physical activity each day (30 ± 16.8 minutes), thus meeting the ACSM guidelines.
37
   On 
average, all subjects participated in physical activity 5 ± 0.71 days/ week.  No subjects 
engaged in very vigorous activity.  Subjects walked 5481 ± 2200 steps/day. 
Oxygen Consumption 
There were significant differences between predicted oxygen consumption 
between the OSA and control groups (p<0.05) as seen in Table 4 which can be attributed 
to the age difference between groups.  However, there were no differences between 
groups for oxygen consumption, respiratory exchange ratio (RER), and systolic blood 
pressure at either intensity (Table 4).  There was a trend for diastolic blood pressure to be 
higher in the OSA group with exercise, but it did not reach statistical significance 
(p=0.067).  Both groups had a significantly higher oxygen consumption (VO2) at both 
intensities than predicted VO2 as seen in Table 4 (p<0.001). 
Heart Rate Variability 
Resting HRV data is shown in Table 5.  SDNN, RMSSD, and TotalPower were 




were no group differences in HF and LF.  There was a significant main effect for age in 
both HF (p=0.027) and LF (p=0.041).  An ANCOVA was used for HF and LF with age 
as the covariate. 
Exercise HRV data is presented in Table 5.  During exercise, there was a 
significant main effect for intensity, as SDNN and HF decreased as the intensity 
increased.  There was no main effect for group.  During exercise, there was a significant 
main effect for intensity, as RMSSD and LF increased as the intensity increased.  There 
was no main effect for group.  For LFnu and HFnu there was no main effect for intensity, 
but there a trend towards a main effect for group with the OSA group higher (p=0.066 
and p=0.075 for LFnu and HFnu, respectively) (Figure 1A and 1B).  There was no 
significant main effect for intensity for LF-HF ratio; however, there was a significant 
main effect for group.  The OSA group had a significantly lower LF-HF ratio compared 
to the control group (Figure 1C). 
Discussion 
 This study confirms the findings of previous research on the autonomic function 
of the OSA population at rest.  During rest we saw lower values in SDNN, total power 
(TP), and RMSSD in the OSA group indicating overall decreased HRV in this 
population.  SDNN represents a general picture of HRV, with a lower SDNN indicating a 
lack of balance between sympathetic and parasympathetic activity or an autonomic 
dysfunction
38
  A lower SDNN further suggests that the body is unable to maintain 
homeostasis in the presence of internal and external stressors.
39
  A lower TP variable also 
shows a decrease in total HRV, again providing evidence of autonomic dysfunction in 




withdrawal, sympathetic dominance, or a combination of both.
40
  The autonomic 
dysfunction at rest in this population is seen by increased sympathetic activity and 
decreased parasympathetic activity.
41




 A unique and major finding in our study was that during steady-state exercise 
HFnu (i.e. parasympathetic activity) in the OSA group did not change significantly 
between rest and exercise (Figure 1B).  Moreover, the significant reduction in the LF-HF 
was at least partially attributable to the unchanged HFnu (Figure 1C).  The initial increase 
from rest to light intensity in the LF-HF ratio during can be attributed to vagal 
withdrawal rather than sympathetic stimulation.
45
  The decrease in the ratio from light to 
vigorous intensity was expected since the balance between the sympathetic and 
parasympathetic systems decreases in proportion to the exercise intensity (Figure 1C).
45
  
The OSA group had a significantly lower LF-HF ratio during exercise (Table 5, Figure 
1C).  The LF-HF ratio represents the balance between the sympathetic and 
parasympathetic systems.
38
  A higher LF-HF ratio would indicate increased sympathetic 
dominance, while a lower LF-HF ratio would indicate an increased parasympathetic 
dominance.
39
  The lower LF-HF ratio in the OSA group could potentially be explained by 
the HFnu variable during steady-state exercise.  The HFnu did not change between rest 
and vigorous intensity in the OSA group (Table 5, Figure 1B).  In a normal, healthy 
individual during early exercise, there is vagal withdrawal and increased sympathetic 
activity ultimately increasing the individual’s heart rate.
45,46
  As exercise duration 
continues and intensity increases, sympathetic activity also increases.
45,46
  In this study, 




sympathetic excitation.  Parasympathetic activity did not change significantly among the 
three conditions in the OSA group.  The lack of parasympathetic withdrawal could be the 
link to autonomic dysfunction in this population. 
During exercise, the OSA group was trending towards a higher main effect for 
group in terms of HFnu (p=0.075, Table 5, Figure 1B).  This indicates a lack of 
parasympathetic response during exercise in the OSA group.  Though the difference at 
rest is not statistically significant, it may suggest that people with OSA inherently have a 
lower level of parasympathetic activity.  The OSA group was trending towards a 
significantly higher main effect for group in terms of LFnu (p=0.066, Table 5, Figure 
1A).  This is in agreement with previous literature since people with OSA have 
sympathetic dominance.
44
  Alameri et al. attributed increases in blood pressure and heart 
rate and delayed return to resting heart rate in an OSA group during a 6 minute walk test 
to sympathetic overdrive and delayed parasympathetic activity.
47
  The increase in 
breathing frequency and tidal volume that occurs during exercise may have been 
accelerated in the OSA group which would result in higher HFnu values compared to the 
control group.
48
  The lack of parasympathetic withdrawal may cause the decreased HRV 
by not allowing the heart rate to vary as much during exercise.  This could be the link to 
autonomic dysfunction in this population.  
Potential mechanisms for the autonomic dysfunction in the OSA population 
include the decreased baroreceptor sensitivity and heightened chemoreceptor sensitivity.  
Baroreceptors are part of a homeostatic mechanism to keep blood pressure regulated.  If 
blood pressure increases, the baroreceptors send signals to the brain to decrease 




ultimately allowing for the blood to flow through the vessels with less pressure.
49
  
Repetitive hypoxias that occur in people with OSA cause increases in blood pressure.  In 
the presence of hypoxias and constant blood pressure variability, the baroreceptors 
become desensitized to higher pressures.
13,40
  This decreased sensitivity in these receptors 
increases likelihood of increased sympathetic activity and hypertension in this 
population.
14,50
  Chemoreceptors are also very important in people with OSA since they 
detect decreases in oxygen saturation.
51
  When these receptors sense oxygen desaturation, 
the sympathetic nervous system is heightened and constricts vessels thereby increasing 
blood pressure. 
14,42,51-54
  The actions of both baroreceptors and chemoreceptors cause 




 One limitation in the study was the small sample size.  A larger sample size would 
allow for a stronger effect size and potentially the trends for LFnu and HFnu would be 
statistically significant.  However, the sample size was large enough to produce a 
significant difference in LF-HF ratio. 
 In conclusion, people with OSA have lower HRV at rest which has been 
confirmed by previous research.  This study found a lower LF-HF ratio during steady-
state exercise in the OSA group which may be caused by the blunted parasympathetic 
response in this population.  At rest, the OSA group had a lower starting HFnu variable 
than the control group, though not statistically significant.  The lack of parasympathetic 
withdrawal in the OSA group could be the association to autonomic dysfunction.  Future 
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Table 1—Subject Characteristics 
 
Characteristic OSA 
(n = 10) 
CONTROL 
(n = 16) 
P 
Age 43.7 ± 12.2* 25.6 ± 9.5 < 0.05 
AHI 29.9 ± 23.5* 1.4 ± 1.5 < 0.05 
ESS 8.6 ± 5.6 9.4 ± 5.6 0.71 
Weight (kg) 103.4 ± 23.6* 84.2 ± 11.5 < 0.05 
BMI (kg2/m2) 34.3 ± 6.0* 28.9 ± 3.2 < 0.05 
Waist Circumference (cm) 108.9 ± 14.1* 91.8 ± 9.3 < 0.05 
Neck Circumference (cm) 42.9 ± 4.3* 36.4 ± 3.4 < 0.05 
Resting HR 73.9 ± 8.6 68.6 ± 7.8 0.12 
SBP 120.4 ± 8.4 117.1 ± 8.4 0.34 
DBP 78.0 ± 9.2 75.1 ± 8.0 0.41 
 
Table 1. Data are presented as means ± Standard Deviation. 
*p<0.05 
AHI = apnea-hypopnea index; ESS = Epworth Sleepiness Scale; BMI = body mass index; 































Table 2—Physical Activity (PA) Data 
 
Measure of PA 
 
OSA CONTROL 
IPAQ (MET-min/week) 1232.67 ± 1312.91 2395.82 ± 1329.72 
Number of days/week of PA 5.40 ± 0.52 5.07 ± 0.80 
Number of sedentary bouts/day 17.82 ± 4.83 17.20 ± 6.14 
Time per sedentary bout (min) 21.80 ± 3.16 21.32 ± 4.76 
Sedentary time/day (min) 586.62 ± 146.61 564.10 ± 161.05 
Light PA (min) 139.48 ± 70.03 137.64 ± 50.05 
Lifestyle PA (min) 75.15 ± 53.20 47.86 ± 17.36 
Moderate PA (min) 31.43 ± 16.74 30.45 ± 17.37 
Vigorous PA (min) 1.66 ± 3.69 0.93 ± 1.32 
Very Vigorous PA (min) 0.00 ± 0.00 0.05 ± 0.19 
Steps/day 5486.62 ± 2524.99 5478.24 ± 2037.97 
 
Table 2. Data are presented as means ± Standard Deviation. No differences between 
groups. 































Table 3—Sleep Data 
 
Sleep Variable OSA CONTROL P 
Sleep Latency (min) 4.96 ± 2.87 3.54 ± 3.82 0.328 
Sleep Efficiency (%) 79.12 ± 10.92 88.36 ± 6.30 0.013* 
Total Sleep Time (min) 362.89 ± 79.03 388.50 ± 55.79 0.351 
Number of Awakenings 19.88 ± 7.09 14.90 ± 6.89 0.094 
Avg. Length of Awakening (min) ǂ 5.07 ± 3.30 3.28 ± 1.03 0.069 
Total Time in Bed (min) 409.35 ± 25.92 470 ± 19.39 0.115 
Wake After Sleep Onset 69.17 ± 15.79 64.20 ± 12.02 0.830 
 
Table 3. Data are presented as means ± Standard Deviation.  
* Significant, p<0.05 




Table 4—Oxygen Consumption 
Measured Variables OSA CONTROL P (intensity) P (between groups) 
VO2max prediction 28.0 ± 4.7 35.3 ± 4.4 -- <0.05* 
Predicted 35% VO2R 9.4 ± 2.3 11.4 ± 1.7 -- <0.05* 
Predicted 70% VO2R 18.4 ± 3.7 22.8 ± 3.3 -- <0.05* 
 
Oxygen Consumption ǂ 
     Light Intensity 
     Vigorous Intensity 
 
17.26 ± 2.58° 
23.98 ± 4.83° 
 
18.03 ± 2.93° 






     Light Intensity 
     Vigorous Intensity 
 
0.88 ± 0.05 
0.97 ± 0.04 
 
0.89 ± 0.06 
0.99 ± 0.05 
0.00* 0.702 
Systolic BP ǂ (mmHg) 
     Light Intensity 
     Vigorous Intensity 
 
180.52 ± 21.0 
198.79 ± 26.05 
 
157.60 ± 17.97 
173.87 ± 17.44 
0.00* 0.348 
Diastolic BP (mmHg) 
     Light Intensity 
     Vigorous Intensity 
 
91.46 ± 11.38 
94.22 ± 12.46 
 
83.33 ± 9.28 
84.80 ± 10.90 
0.105 0.067 
 
Table 4. Data are presented as means ± Standard Deviation. 
* Significant, p<0.05 
° Significantly higher than predicted oxygen consumption, p<0.001 
ǂ Data adjusted for age. 
VO2max = maximal oxygen consumption 
RER = Respiratory exchange ratio 

















Table 5—HRV Data 
HRV Variable  Intensity  
 Rest¤ Light Vigorous 
SDNN(ms) *#    
     OSA 1.57 ± 0.31 0.80 ± 0.16 0.67 ± 0.18 
     CONTROL 1.85 ± 0.29 1.05 ± 0.27 0.76 ± 0.41 
RMSSD(ms)*#    
     OSA 1.37 ± 0.27 0.49 ± 0.18 0.59 ± 0.28 
     CONTROL 1.78 ± 0.37 0.45 ± 0.12 0.47 ± 0.25 
Total Power(ms
2
)*°#    
     OSA 3.26 ± 0.65 1.82 ± 0.49 1.28 ± 1.44  
     CONTROL 3.79 ± 0.57 2.24 ± 0.65 1.44 ± 0.86 
VLF(ms
2
)°#    
     OSA 3.02 ± 0.76 1.73 ± 0.53 1.24 ± 0.34 
     CONTROL 3.44 ±0.56 2.17 ± 0.64 1.40 ± 0.86 
LFnu    
     OSA 52.36 ± 18.47 62.39 ± 20.81 72.66 ± 19.70 
     CONTROL 40.32 ± 20.47 51.37 ± 22.54 66.52 ± 18.26 
HFnu    
     OSA 47.64 ± 18.47 37.51 ± 20.87 48.17 ± 22.86 
     CONTROL 59.77 ± 20.47 27.32 ± 19.71 33.86 ± 18.10 
LF-HF Ratio(ms
2
)**    
     OSA 2.04 ± 0.35 2.25 ± 0.44 2.03 ± 0.45 
     CONTROL 1.81 ± 0.40 2.51 ± 0.45 2.34 ± 0.39 
LF(ms
2
)ǂ#    
     OSA 2.51 ± 0.58 0.598 ± 0.36 1.15 ± 0.75 
     CONTROL 3.03 ± 0.52 -0.16 ± 0.34 0.11 ± 0.86 
HF(ms
2
)ǂ#    
     OSA 2.46 ± 0.45 0.34 ± 0.49 -0.19 ± 0.49 
     CONTROL 3.22 ± 0.70 0.65 ± 0.80 -0.23 ± 0.82 
*p<0.05, significant difference at rest between groups 
**p<0.05, significant main effect for group during exercise 
#p<0.05, significant main effect for intensity during exercise 
ǂ adjusted for age at rest. 
° adjusted for age during exercise. 













Figure 1—LFnu (A), HFnu (B), and LF-HF Ratio (C) between OSA and Control at rest, 






All figures presented as means ± SD. 
*p<0.05, LF-HF ratio is significantly lower in the OSA group compared to the control group. 
A. During exercise, LFnu is trending higher in the OSA group towards a main effect for group. 



































































James Madison University 
Department of Kinesiology 
Informed Consent 
Purpose 
You are being asked to volunteer for a research project conducted by Dr. Trent Hargens 
from James Madison University entitled, “The effects of obstructive SLEEP apnea on 
AUTONOMIC and cardiovascular FUNCTION during steady-state EXERCISE”, or 
the SAFE study. 
The primary goals of this study is to examine whether individuals who are newly 
identified as high risk for, or diagnosed with, obstructive sleep apnea (OSA) have show 
altered heart rate and cardiovascular variables during sub-maximal exercise.  This may 
provide a clearer picture into why OSA increases the risk for other chronic health 
problems. 
Experimental Procedures 
You will be asked to visit the Human Performance Laboratory (HPL) in Godwin Hall 3 
times over the course of about 7 – 10 days.  Your total time commitment for participation 
in this study will be approximately 2 and a half hours.  In addition, you will be asked to 
wear (for one night) an at-home sleep testing device (the ApneaLink) to screen you for 
possible OSA.   It is equipped with straps, a finger probe, and a nasal cannula. It 
measures your breathing activity, heart rate, and blood oxygen levels, and is harmless to 
wear.   Also, you will be asked to wear a device (an accelerometer) on your waist during 
the day for a period of 4 days, including 1 weekend day, while wearing the same device 
on your wrist at night while you sleep.  Detailed information on each visit is provided 
below: 
Visit 1 
Before any test is given, you will be asked to complete a screening form and an informed 
consent, to insure that you meet the study criteria, that you do not have any factors that 
would disqualify you from participation.  Upon completion of the informed consent, you 
will be asked to complete a short health history questionnaire providing information 
about your characteristics and health.  You will then be asked complete 3 standardized 
questionnaires about snoring, the quality of your sleep, daytime sleepiness, and risk for 
OSA. 
You will then have your height, weight, waist circumference and neck circumference 
measured.  After that, your body composition will be analyzed via a Dual-energy x-ray 
absorptiometer (DEXA).  The DEXA scan will allow us to measure your percent body fat 
and the mineral content and density of your bones.  The DEXA is much like an X-ray 
machine.  The DEXA will scan your entire body very slowly; so, you will need to lie on a 
table without moving for almost 10 minutes, while the DEXA is passed over your entire 




At the end of this first visit you will also be instructed on the proper use procedures for 
wearing the ApneaLink device for your one-night sleep assessment, as well as 
instructions on wearing the accelerometer.  An accelerometer is a small device that is to 
be worn on your waist during the day and on your wrist while in bed.   
Following the DEXA scan, we will ask that you wear a heart rate monitor while lying 
down in a darkened room for 15 minutes to get measures of your heart rate.  We will also 
obtain your resting blood pressure. 
Visit 2 
The following day after Visit 1, you will be asked to return to the HPL to return the 
ApneaLink device.  Following this, we will ask that you wear a heart rate monitor while 
lying down in a darkened room for 15 minutes to get measures of your heart rate.  We 
will also obtain your resting blood pressure.  This visit should take about 30 minutes. 
Visit 3 
Approximately 5 – 6 days later, you will be asked to return to the HPL for your final 
visit.  For this visit you will undergo a submaximal treadmill exercise test.  You will be 
asked to walk on the treadmill for a total of about 15 minutes, which includes a 3 – 4 
minute warm-up, and 2 – 3 minute cool-down.  In between the warm-up and cool-down 
you will be asked to walk at 2 separate workloads, 1 fairly easy, and 1 somewhat hard, 
for 5 minutes at each workload.  During this test we will monitor the electrical output of 
your heart by placing electrodes directly on your skin across your chest, stomach and 
back.  A female researcher will be available to place and remove electrodes for female 
subjects.  During the test, we will measure the electrical activity of your heart, your heart 
rate, blood pressure, your effort, and how much oxygen your body is using.  To see how 
much oxygen you use, we will ask you to breathe into a rubber mouthpiece.  .  During the 
test, you will breathe only through the mouthpiece and may experience some dryness in 
your mouth.  Prior to your arrival to the HPL for this visit, you will be asked to consume 
a normal meal (breakfast or lunch) and not to come to the HPL with a full stomach. 
Risks 
There are no risks associated with wearing an accelerometer.  Also, there is no risk 
associated with heart rate, blood pressure, height, weight, and waist and neck 
circumference measures.  You will not be asked to change any of your personal habits 
during the course of the study. Measurements with associated risks include:  the DEXA 
scan and treadmill exercise test.   
The amount of radiation that you will receive in the DEXA exam is less than the amount 
you will receive during a transatlantic flight, and is equal to about 1/20 of a chest x-ray.  
You should not be pregnant for this study because of risks from the DEXA scan radiation 
to the embryo or fetus.  If you feel that you might be pregnant, inform the research staff 
immediately. 
There is a risk of abnormal changes during the submaximal treadmill exercise test.  These 




heart attack, and death.  The chance of serious heart problems during maximal exercise 
among adults is very small (less than 1/10,000 maximal exercise tests).  The exercise trial 
for this proposed study is sub-maximal vs. maximal, so the risk for complications is even 
less.  Every effort will be made to minimize risks of an abnormal response by reviewing 
you health history and providing adequate supervision of the exercise test.  All staff are 
certified by the American Heart Association in BLS (Basic Life Support). 
Benefits 
There is no guarantee that you will get any benefit from taking part in this study.  
Benefits may include knowledge about your health status.  You will receive information 
on your body composition, including percent body fat and bone mineral density, an 
assessment of your sleep quality and risk for sleep apnea, an assessment of your physical 
activity level, and cardiovascular fitness.  Indirect benefits of participating in this study 
will be helping the researchers better understand the relationship between habitual 
snoring, sleep apnea, and cardiovascular disease risk. 
Inquiries 
If you have any questions or concerns or you would like to receive a copy of the final 
aggregate results of this study, please contact Dr. Trent Hargens at hargenta@jmu.edu or 
(540) 568-5844.  
Questions about Your Rights as a Research Subject 
Dr. David Cockley 
Chair, Institutional Review Board 




All data and results will be kept confidential. You will be assigned an identification code. 
At no time will your name be identified with your individual data. The researcher retains 
the right to use and publish non-identifiable data. All data will be kept secured in a 
locked cabinet. All electronic data will be kept on a password-protected computer.  Final 
aggregate results will be made available to participants upon request. 
Freedom of Consent 
Your participation is entirely voluntary.  You are free to choose not to participate.  






I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 
certify that I am at least 18 years of age. 
_______________________________ ___________________________________ 
Name of Subject (Printed)   Name of Researcher (Printed) 
_______________________________ ___________________________________ 
Name of Subject (Signed)   Name of Researcher (Signed) 
_______________________________ ___________________________________ 

















































Epworth Sleepiness Scale 
 
 
Subject ID____________________________________ Date Completed ____/____/____ 
 
This questionnaire asks you to indicate the chances of you becoming drowsy during 
hours of the day that you are not in bed sleeping.  “How likely are you to doze off or fall 
asleep in the following situations?” 
 
Use the following scale and indicate the most appropriate number for each situation. 
 
    0 = would never doze 
    1 = slight chance of dozing 
    2 = moderate chance of dozing 
    3 = high chance of dozing 
 
 Situation       Chance of Dozing 
 
1. Sitting and reading       _____ 
2. Watching T.V.       _____ 
3. Sitting, inactive in a public place 
 (ex.  Theatre or meeting)      _____ 
4. As a passenger in a car for 
 an hour without a break      _____ 
5. Lying down to rest in the afternoon 
 when circumstances permit      _____ 
6. Sitting and talking with someone     _____ 




8. In a car, while stopped for a few minutes in traffic   _____ 
 

























































Subject ID____________________________________ Date Completed ____/____/____ 
 
Height (cm) ___________ Weight (kg) _________ Age _____ 
 
Please choose the correct response to each question. 
Category 1  
1. Do You Snore? 
☐ a. Yes 
☐ b. No 
☐ c. Don’t know 
 
If you snore: 
2. Your snoring is: 
☐ a. Slightly louder than breathing 
☐ b.  As loud as talking 
☐ c.  Louder than talking 
☐ d.  Very loud – can be heard in  
 adjacent rooms 
3. How often do you snore? 
☐ a.  Nearly every day 
☐ b.  3-4 times a week 
☐ c.  1-2 times a week 
☐ d.  1-2 times a month 






4. Has your snoring every bothered 
other people? 
☐ a.  Yes 
☐ b.  No 
☐ c.  Don’t Know 
5. Has anyone noticed that you quit 
Breathing during your sleep? 
☐ a.  Nearly every day 
☐ b.  3-4 times a week 
☐ c.  1-2 times a week 
☐ d.  1-2 times a month 
☐ e.  Never or nearly never 
 
Category 2 
6. How often do you feel tired or fatigued after you sleep? 
☐ a.  Nearly every day 
☐ b.  3-4 times a week 
☐ c.  1-2 times a week 
☐ d.  1-2 times a month 
☐ e.  Never or nearly never 
7. During your waking time, do you feel tired, fatigued or not up to par? 
☐ a.  Nearly every day 
☐ b.  3-4 times a week 
☐ c.  1-2 times a week 
☐ d.  1-2 times a month 





8. Have you ever nodded off or fallen asleep while driving a vehicle? 
☐ a. Yes 
☐ b. No 
If yes: 
9. How often does this occur? 
☐ a.  Nearly every day 
☐ b.  3-4 times a week 
☐ c.  1-2 times a week 
☐ d.  1-2 times a month 
☐ e.  Never or nearly never 
 
Category 3 
10. Do you have high blood pressure? 
☐ a.  Yes 
☐ b.  No 














































Subject ID___________________________________ Date Completed ____/____/____ 
Height (Inches) ___________ Weight (lbs) _________ Age _____ 
Neck Circumference (cm) ____________ 
The STOP Test consists of four questions: 
1. Snoring  
Do you snore loudly (louder than talking or loud enough to be heard through closed 
door)?          Yes No  
2. Tired  
Do you often feel tired, fatigued or sleepy during the day?   Yes No  
3. Observed  
Has anyone observed you stop breathing during your sleep?  Yes No  
4. Blood Pressure  






High risk of OSA: answering yes to two or more questions  









































Medical and Health History Form  
 
Name:       Date of Birth: ________________ 
Ethnicity:    
Height:     ft Weight:     pounds 
Gender:  Female   Male   
Campus Address:             
Campus Telephone Number: ____________________ 
Campus Email Address: _____________________ 
Address for Permanent Residence:  ________________________________________________________ 
Person to contact in case of emergency:  _____________________________________________________ 
Relationship:  _____________    Daytime Telephone: ____________ Home Telephone:     
Primary Care Physician:   ________________________          Telephone:      
Medical History 
Please indicate any current or previous conditions or problems you have experienced or have been told by a 
physician you have had:  
  Yes     No 
Heart disease or any heart problems:   _____   _____ 
Rheumatic fever:      _____   _____ 
Respiratory disease or breathing problems:   _____   _____ 
Circulation problems:     _____   _____ 
Kidney disease or problems:    _____   _____ 
Urinary problems:     _____   _____ 




Musculoskeletal problems:    _____   _____ 
Fainting or dizziness, especially with exertion:  _____   _____ 
Neurological problems/disorders:    _____   _____ 
High blood pressure:     _____   _____ 
Low blood pressure:     _____   _____ 
High blood cholesterol:      _____   _____ 
Diabetes:      _____   _____ 
Thyroid problems:     _____   _____ 
Eating disorders (bulimia, anorexia):   _____   _____  
Allergies:      _____   _____ 
If "yes" to any of the above please indicate the date, explain, and describe: 
            
             
Please list any hospitalizations/operations/recent illnesses (Type/Date):     
      
       
Do you ever feel faint, short of breath, or chest discomfort with exertion? Yes: ________    No: ________ 
If "yes", please explain :          
           
Are there any orthopedic limitations you have that may restrict your ability to perform hard running 
exercise or intense strength-type exercises?  (back, hips, knees, ankles)    Yes                        No  _____ 
If  "yes" please explain:       






Family Health History 
Has anyone in your family (blood relatives only) been diagnosed or treated for any of the following? 
   Yes  No    Relationship   Age 
Heart attack _____  _____      _____ 
Heart disease _____  _____      _____ 
High blood pressure _____  _____      _____ 
Stroke _____  _____      _____ 
Kidney disease _____  _____      _____ 
Diabetes  _____  _____      _____ 
Health Habits 
Do you add salt to your food?  Yes  ___   No  ___   Are you on any special type of diet?  Yes  ___   No ___ 
If "yes" please describe          
             
Do you drink caffeinated beverages?  Yes  _____   No ______     How many cups per day?                       
Do you drink alcoholic beverages?     Yes  _____     No  ______  How many drinks per week? _________ 
What is the average number of drinks that you consume on the weekend? _________ 
Did you use tobacco products in the past (more than 12 months ago)? Yes ______     No _______ 
Sleep Habits Evaluation 
Do you have episodes of parasomnias (disorders such as sleep walking, sleep talking, night terrors, body 
rocking, bedwetting that will cause partial or full awakening?)   Yes            No  
Do you show signs of sleep disturbances (such as insomnia, daytime sleepiness) when you are anxious, 
stressed?   Yes     No   
Do you have difficulties to fall asleep if a certain object or a certain situation is absent such as listening to 




Do you have difficulties to fall asleep earlier or later of your usual bedtime? Yes    No   
Do you wake up at night to get a little snack? Yes   No   
If “yes”, do you think that the snack is helping you to go back to sleep? Yes   No   
Do you have hallucinations (vivid images that look like dreams occurring when you sleep) or find yourself 
physically weak or paralyzed for a few seconds?                Yes            No   
Tonsils and Adenoids evaluation questionnaire 
Do you have a history of recurrent tonsillitis which is an inflammation of the tonsils (clusters of tissue that 
lie in bands on both sides of the back of the throat) caused by an infection? In tonsillitis, the tonsils are 
enlarged, red, and often coated either partly or entirely?  Yes    No   
Did you ever have inflammation of the adenoids (single clump of tissue in the back of the nose) causing a   
blockage of the back of the nose, chronic and recurrent fluid or infections of your ears, or chronic or 
recurrent sinus infections?                                 Yes   No   
Did you have tonsillectomy (tonsils removed) or adenoidectomy (adenoids removed)? Yes   No  
Medications 
Please list all medications (prescription and over-the-counter) you are currently taking or have taken in the 
past week:            
             
Please sign to indicate the above information is correct: 
 ____         
   Print Name       Signature                                    Date 
 
Follow Up Review and Interview by:                   ____________________________________ 
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